Evidence-based male sexual health
Evidence from meta-analyses of 50,000+ clinician-measured men
| Percentile | Length | Girth | Meaning |
|---|---|---|---|
| 5th | 9.85 cm (3.88") | 9.0 cm (3.54") | Smaller than 95% of men |
| 10th | 10.7 cm (4.21") | 9.7 cm (3.82") | Smaller than 90% of men |
| 25th | 11.6 cm (4.57") | 10.5 cm (4.13") | Smaller than 75% of men |
| 50th | 13.0 cm (5.12") | 11.6 cm (4.57") | Average (median) |
| 75th | 14.5 cm (5.71") | 12.7 cm (5.00") | Larger than 75% of men |
| 90th | 15.5 cm (6.10") | 13.4 cm (5.28") | Larger than 90% of men |
| 95th | 16.0 cm (6.30") | 14.0 cm (5.51") | Larger than 95% of men |
| Abbreviation | Name | Description |
|---|---|---|
| BPEL | Bone-Pressed Erect Length | Gold standard. Rigid ruler pressed into pubic bone along dorsal surface to glans tip. Accounts for fat pad variation. |
| NBPEL | Non-Bone-Pressed Erect Length | Measured from skin surface without pressing into fat pad. Reflects visible length; varies with body fat. |
| BPFSL | Bone-Pressed Flaccid Stretched Length | Flaccid penis stretched to maximum; measured from pubic bone. Correlates with BPEL at r=0.7–0.9 (Chen et al. 2000). Research proxy when erection not feasible. |
| EG | Erect Girth (Circumference) | Measured at widest point (usually mid-shaft) with non-stretchable tape during full erection. |
| Region | Erect Length | Studies | Confidence |
|---|---|---|---|
| Africa | ~14.6 cm* | Orakwe et al. 2006 (Nigeria, n=115): 13.4cm; limited clinician-measured data overall | Low |
| Western Europe | ~13.5 cm | Ponchietti 2001 (Italy, n=3,300): 12.5cm; Multiple UK, German studies | High |
| North America | ~13.3 cm | Wessells 1996 (US, n=80): 12.9cm | Moderate |
| South America | ~13.7 cm* | Limited clinician-measured data | Low |
| East Asia | ~12.5 cm | Chen 2000 (Taiwan, n=1,000): 11.5cm; Yoon 1998 (Korea, n=150): 12.7cm; Wang 2025 Chinese meta-analysis | High |
| South Asia | ~13.0 cm | Promodu 2007 (India, n=2,700): 13.01cm | Moderate |
| Middle East | ~12.8 cm | Mehraban 2007 (Iran, n=1,500): 11.6cm | Moderate |
Individual variation within any ethnic group spans over 7 cm (≈10th to 95th percentile). Between-group average differences are typically 0.5–1.5 cm. This makes within-group variation 15–30x greater than between-group, rendering population averages nearly useless for predicting individual size.
WHO Regions Meta-Analysis 2025; Veale 2015
After adjusting for geographic region, age, and population, erect penile length increased 24% over 29 years (1942–2021). Hypothesized causes: improved childhood nutrition, earlier puberty onset, rising obesity (paradoxically), and endocrine disruptor exposure. This trend needs independent replication.
Herbenick et al. 2023, World J Men's Health
Clinician-measured vs self-reported studies consistently show men over-report by 1–2 cm due to social desirability bias. The Veale 2015 meta-analysis ONLY included clinician-measured data, making it the most reliable reference. Self-reported online surveys should be disregarded.
Veale 2015; Richters et al. 2006
The suprapubic fat pad can bury 1–3 cm of shaft. BPEL (bone-pressed) remains unchanged, but visible NBPEL decreases. Yafi et al. 2018 (Sex Med Rev) quantified this: higher BMI = more concealed length. Weight loss doesn't grow the penis — it reveals what's already there.
Yafi et al. 2018, Sexual Medicine Reviews
A 2018 IJImpR study categorized: 24% "growers" (>50% increase flaccid→erect), 26% "showers" (<30% increase), 50% average (30-50%). Flaccid-to-erect correlation is only r=0.2–0.5. BPFSL is a much better predictor (r=0.7–0.9).
Veale 2015; Wessells 1996; IJIR 2018
Lever et al. 2006 (n=52,031): 85% of women satisfied with partner's size. Only 55% of men satisfied with their own. Eisenman 2001: 90% of women (45/50) said width matters more than length. Prause 2015 3D model study: women preferred 6.4" for one-time vs 6.3" for long-term — a trivial difference.
Lever et al. 2006; Eisenman 2001; Prause et al. 2015, PLOS ONE
Twin studies suggest moderate heritability (40–60%) for penile dimensions. Key genetic factors: androgen receptor (AR) gene polymorphisms, 5-alpha reductase activity, and HOX genes (HOXA13) for genital patterning. No single "penis size gene" identified — it's polygenic.
Eisenberg 2013; Bin-Abbas 1999; Hughes 2012
Weeks 8–12 of gestation are the critical window: fetal testosterone → DHT via 5-alpha reductase → drives penile development. Insufficient DHT (as in 5-alpha reductase deficiency) causes micropenis/ambiguous genitalia. After puberty, exogenous testosterone does NOT increase adult penis size.
Wilson et al. 1995; Imperato-McGinley 1974; Baskin 2001
| Age | Size | Tanner Stage | Note |
|---|---|---|---|
| Birth | ~3.5 cm stretched | Tanner I | Micropenis if <1.9cm stretched (>2.5 SD below mean). Feldman & Smith 1975. |
| 1–5 years | ~4–5 cm | Tanner I | Minimal growth. Pre-pubertal quiescence. |
| 6–8 years | ~5–6 cm | Tanner I | Adrenarche may begin; no significant penile growth yet. |
| 9–11 years | ~6–9 cm | Tanner II | Testicular enlargement begins (>4mL volume). First pubic hair. |
| 12–14 years | ~8–12 cm | Tanner III–IV | Peak growth velocity. Testosterone surges drive rapid elongation and girth increase. |
| 15–17 years | ~11–14 cm | Tanner IV–V | Approaching adult size. Marshall & Tanner 1970. |
| 18–21 years | ~12–15 cm | Tanner V | Final adult size reached. Growth ceases with epiphyseal closure equivalent. |
| 40–50 years | Stable | — | BPEL stable. NBPEL may decrease if weight gain increases fat pad. |
| 50–60 years | May decrease 0.5cm | — | Reduced elasticity of tunica albuginea; corporal fibrosis begins. Bondil 1992. |
| 60+ years | May decrease 0.5–1cm | — | Progressive fibrosis, reduced blood flow, increased fat pad. El-Sakka 1998. |
Definition: Stretched penile length >2.5 SD below the mean for age. Neonate: <1.9cm. Adult: <7.5cm stretched (or <9.32cm BPEL).
Prevalence: 0.6% of male births (1 in 166)
Causes: Hypogonadotropic hypogonadism (Kallmann syndrome, GnRH deficiency), hypergonadotropic hypogonadism (Klinefelter 47,XXY), 5-alpha reductase deficiency, partial androgen insensitivity, growth hormone deficiency, idiopathic (~20%)
Treatment: Infant: testosterone enanthate 25-50mg IM q3-4wks x 3 months. DHT cream 2.5%. Expect ~100% length increase. Adult: limited options (traction, surgery).
StatPearls 2024; Lee 1980; Bin-Abbas 1999
Definition: Fibrous plaque formation in the tunica albuginea causing penile curvature, pain, and often shortening.
Prevalence: 3–9% of men; up to 20% in autopsy studies. Peak onset 50–60 years.
Causes: Microtrauma during intercourse → abnormal wound healing → collagen plaque. Genetic predisposition (Dupuytren's association). Acute phase (painful, evolving) → Stable phase (pain resolves, deformity fixed).
Treatment: Acute: PDE5i, traction (RestoreX), intralesional verapamil/interferon. Stable: Xiaflex (collagenase), plication, plaque incision+grafting, penile prosthesis. 2024 PTNM classification: classical, nonclassical, calcifying, progressive, relapsing/remitting.
AUA Guidelines; Mulhall 2006; PTNM 2024, J Urol
Definition: Penis concealed beneath prepubic fat pad, scrotal skin, or cicatricial tissue. Normal underlying penile size.
Prevalence: Increasing with obesity epidemic. Congenital form: rare.
Causes: Adult-acquired: obesity (primary), prior radical circumcision, lichen sclerosus. Congenital: deficient dartos attachment.
Treatment: Weight loss first. Surgical: suprapubic lipectomy, panniculectomy, escutcheonectomy, skin grafting. Outcomes: 293% increase in flaccid visible length post-surgery (Xiang 2025).
PMC 2018; Xiang 2025, BJUI Compass
Definition: Subtype of BDD: severe preoccupation with perceived inadequacy of penis size, despite objectively normal dimensions.
Prevalence: BDD overall: ~1.9%. PDD subset: unknown but significant among men seeking enlargement.
Causes: Mondaini 2002 (Eur Urol): 67 men seeking surgery — NONE (0%) had a short penis by nomogram. 100% were within normal range. 65.7% complained only about flaccid length. Porn exposure, media influence, childhood teasing.
Treatment: CBT (cognitive-behavioral therapy) + SSRIs. Surgery is CONTRAINDICATED — does not resolve distress and may worsen it. Veale PDD screening scale differentiates PDD from normal size anxiety.
Mondaini 2002; Veale 2015 PDD scale; ISSM Guidelines